Published in J Pathol on March 01, 2009
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol (2009) 3.21
The molecular pathogenesis of osteosarcoma: a review. Sarcoma (2011) 1.91
Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol (2010) 1.68
Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas. Int J Cancer (2010) 1.28
IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. BMC Cancer (2013) 1.03
Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer (2010) 1.03
Prognostic value of IGF-1R expression in bone and soft tissue sarcomas: a meta-analysis. Onco Targets Ther (2015) 0.98
Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives. Sarcoma (2011) 0.96
Prognostic and predictive role of CXCR4, IGF-1R and Ezrin expression in localized synovial sarcoma: is chemotaxis important to tumor response? Orphanet J Rare Dis (2015) 0.95
A set of imprinted genes required for normal body growth also promotes growth of rhabdomyosarcoma cells. Pediatr Res (2012) 0.95
Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth. Cancer Biol Ther (2014) 0.93
Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad? Invest New Drugs (2012) 0.92
R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis. PLoS One (2011) 0.92
Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507. Clin Cancer Res (2011) 0.91
Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1. PLoS One (2009) 0.91
New therapeutic targets in soft tissue sarcoma. Adv Anat Pathol (2012) 0.89
Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression. Front Oncol (2013) 0.88
Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma. PLoS One (2012) 0.88
The molecular biology of soft-tissue sarcomas and current trends in therapy. Sarcoma (2012) 0.88
Nephroblastoma overexpressed (NOV/CCN3) gene: a paired-domain-specific PAX3-FKHR transcription target that promotes survival and motility in alveolar rhabdomyosarcoma cells. Oncogene (2011) 0.87
Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth. Transl Oncol (2013) 0.84
Identification and gene expression profiling of tumor-initiating cells isolated from human osteosarcoma cell lines in an orthotopic mouse model. Cancer Biol Ther (2011) 0.84
Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer. Front Oncol (2013) 0.83
Downstream and intermediate interactions of synovial sarcoma-associated fusion oncoproteins and their implication for targeted therapy. Sarcoma (2012) 0.81
Molecular Analysis of a Recurrent Sarcoma Identifies a Mutation in FAF1. Sarcoma (2015) 0.81
RasGRF1 regulates proliferation and metastatic behavior of human alveolar rhabdomyosarcomas. Int J Oncol (2012) 0.81
New systemic therapy options for advanced sarcomas. Curr Treat Options Oncol (2012) 0.80
New drugs and combinations for the treatment of soft-tissue sarcoma: a review. Cancer Manag Res (2012) 0.80
Flow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcoma. Proc Natl Acad Sci U S A (2015) 0.80
Dural metastasis of Ewing's sarcoma. Surg Neurol Int (2013) 0.79
Targeted therapy in Ewing sarcoma. ISRN Oncol (2012) 0.78
Tissue and serum IGFBP7 protein as biomarker in high-grade soft tissue sarcoma. Am J Cancer Res (2015) 0.78
New insights into signalling-pathway alterations in rhabdomyosarcoma. Br J Cancer (2014) 0.78
Malignant phyllodes tumor of the breast presenting with hypoglycemia: a case report and literature review. Cancer Manag Res (2014) 0.78
PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1. Oncotarget (2015) 0.77
High IGF2 and FGFR3 are associated with tumour progression in undifferentiated pleomorphic sarcomas, but EGFR and FGFR3 mutations are a rare event. J Cancer Res Clin Oncol (2014) 0.77
Cavin-1 and Caveolin-1 are both required to support cell proliferation, migration and anchorage-independent cell growth in rhabdomyosarcoma. Lab Invest (2015) 0.77
Does it make sense to target one tumor cell chemotactic factor or its receptor when several chemotactic axes are involved in metastasis of the same cancer? Clin Transl Med (2016) 0.75
Association between height and malignancy among children in the north of Iran. Iran J Ped Hematol Oncol (2015) 0.75
Clinicopathological characteristics and treatment outcomes of Chinese patients with genitourinary embryonal rhabdomyosarcoma. World J Surg Oncol (2015) 0.75
Non-islet cell tumour hypoglycaemia: A case report. Indian J Anaesth (2016) 0.75
Managing sarcoma: where have we come from and where are we going? Ther Adv Med Oncol (2017) 0.75
Picropodophyllin (PPP) is a potent rhabdomyosarcoma growth inhibitor both in vitro and in vivo. BMC Cancer (2017) 0.75
Prevention of tumour cell apoptosis associated with sustained protein kinase B phosphorylation is more sensitive to regulation by insulin signalling than stimulation of proliferation and extracellular signal-regulated kinase. Mol Cell Biochem (2017) 0.75
Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med (2008) 7.08
Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol (2005) 3.29
Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation (2002) 3.27
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res (2012) 2.95
Metformin: taking away the candy for cancer? Eur J Cancer (2010) 2.68
Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. Endocr Relat Cancer (2007) 2.63
Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis (2003) 2.59
Beliefs and attitudes toward Buruli ulcer in Ghana. Am J Trop Med Hyg (2002) 2.30
Mycobacterium ulcerans disease. Bull World Health Organ (2005) 2.30
Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med (2004) 2.22
Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. J Clin Oncol (2005) 2.14
Risk factors for Buruli ulcer disease (Mycobacterium ulcerans Infection): results from a case-control study in Ghana. Clin Infect Dis (2005) 1.95
TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev (2008) 1.94
Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med (2009) 1.88
Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun (2004) 1.84
Histopathologic features of Mycobacterium ulcerans infection. Emerg Infect Dis (2003) 1.84
Severe cardiac phenotype with right ventricular predominance in a large cohort of patients with a single missense mutation in the DES gene. Heart Rhythm (2009) 1.78
High-grade dysplasia in sporadic fundic gland polyps: a case report and review of the literature. Eur J Gastroenterol Hepatol (2003) 1.77
Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol (2008) 1.76
Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer. J Clin Oncol (2008) 1.63
Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients. J Clin Oncol (2005) 1.62
[18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging (2004) 1.61
The prognostic effect of the number of histologically examined axillary lymph nodes in breast cancer: stage migration or age association? Ann Surg Oncol (2006) 1.58
Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol (2006) 1.57
Desmoglein-2 and desmocollin-2 mutations in dutch arrhythmogenic right ventricular dysplasia/cardiomypathy patients: results from a multicenter study. Circ Cardiovasc Genet (2009) 1.54
Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med (2009) 1.54
The impact of parental cancer on children and the family: a review of the literature. Cancer Treat Rev (2004) 1.52
TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. Clin Cancer Res (2006) 1.52
Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail (2012) 1.51
Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis. Oncogene (2004) 1.50
Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev (2002) 1.50
Epithelioid Hemangioendothelioma: clinicopathologic, immunhistochemical, and molecular genetic analysis of 39 cases. Diagn Pathol (2014) 1.47
Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta (2009) 1.45
Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest (2010) 1.43
Spinal extradural metastasis: review of current treatment options. CA Cancer J Clin (2008) 1.42
Application of the ThinPrep imaging system in urine cytology: a prospective study. Cancer Cytopathol (2013) 1.41
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2011) 1.40
Does sentinel lymph node biopsy in cutaneous head and neck melanoma alter disease outcome? J Surg Oncol (2006) 1.40
Mycolactones and Mycobacterium ulcerans disease. Lancet (2003) 1.39
Analysis of an IS2404-based nested PCR for diagnosis of Buruli ulcer disease in regions of Ghana where the disease is endemic. J Clin Microbiol (2003) 1.33
Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol (2004) 1.31
Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res (2003) 1.29
Factors associated with functional limitations and subsequent employment or schooling in Buruli ulcer patients. Trop Med Int Health (2005) 1.29
Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. J Clin Oncol (2011) 1.28
Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27. J Mol Med (Berl) (2004) 1.27
Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem (2004) 1.27
Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia (2008) 1.25
Epithelioid sarcoma: Still an only surgically curable disease. Cancer (2006) 1.24
The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. Acta Oncol (2009) 1.23
EWSR1-ATF1 chimeric transcript in a myoepithelial tumor of soft tissue: a case report. Hum Pathol (2011) 1.21
A review on pro- and anti-angiogenic factors as targets of clinical intervention. Pharmacol Res (2006) 1.21
The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer (2007) 1.20
The therapeutic challenge of a nonresectable solitary fibrous tumor in a hypoglycemic patient. Int J Clin Oncol (2006) 1.20
Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol (2011) 1.18
Mitral valve surgery for mitral regurgitation caused by Libman-Sacks endocarditis: a report of four cases and a systematic review of the literature. J Cardiothorac Surg (2010) 1.18
Emotional and behavioural functioning of children of a parent diagnosed with cancer: a cross-informant perspective. Psychooncology (2005) 1.18
Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol (2003) 1.17
Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol (2004) 1.15
Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep (2010) 1.15
An oncological view on the blood-testis barrier. Lancet Oncol (2002) 1.15
ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J Nucl Med (2010) 1.14
Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat (2005) 1.13
Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther (2010) 1.13
Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET. Neuroimage (2003) 1.13
Temsirolimus for metastatic desmoplastic small round cell tumor. Pediatr Blood Cancer (2010) 1.11
PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat Rev Clin Oncol (2011) 1.11
The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat (2007) 1.10
Clinicopathologic prognostic factors in myxoid liposarcoma: a retrospective study of 49 patients with long-term follow-up. Ann Surg Oncol (2006) 1.10
Translating TRAIL-receptor targeting agents to the clinic. Cancer Lett (2012) 1.10
Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice. Eur J Cancer (2013) 1.09
Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review. Lancet Oncol (2011) 1.09
Profiling studies in ovarian cancer: a review. Oncologist (2007) 1.09
Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. Int J Cancer (2006) 1.08
Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol (2006) 1.08
Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. Breast Cancer Res Treat (2010) 1.07
Assessment of functional limitations caused by Mycobacterium ulcerans infection: towards a Buruli ulcer functional limitation score. Trop Med Int Health (2003) 1.07
Radiation-induced sarcoma: a challenge for the surgeon. Ann Surg Oncol (2005) 1.06
Variability in axillary lymph node dissection for breast cancer. J Surg Oncol (2004) 1.05
Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int J Cancer (2010) 1.04
Detecting cervical cancer by quantitative promoter hypermethylation assay on cervical scrapings: a feasibility study. Mol Cancer Res (2004) 1.04
Radiation-associated angiosarcoma after breast cancer: high recurrence rate and poor survival despite surgical treatment with R0 resection. Ann Surg Oncol (2012) 1.03
The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. Gynecol Oncol (2009) 1.00
Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. Clin Cancer Res (2009) 0.99
Detection and grading of soft tissue sarcomas of the extremities with (18)F-3'-fluoro-3'-deoxy-L-thymidine. Clin Cancer Res (2004) 0.99
3'-18F-fluoro-3'-deoxy-L-thymidine: a new tracer for staging metastatic melanoma? J Nucl Med (2003) 0.98
Distribution of Buruli ulcer lesions over body surface area in a large case series in Ghana: uncovering clues for mode of transmission. Trans R Soc Trop Med Hyg (2005) 0.97
18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET. J Nucl Med (2004) 0.97
Fas receptor-mediated apoptosis: a clinical application? J Pathol (2002) 0.97
Tumor necrosis factor-related apoptosis-inducing ligand pathway and its therapeutic implications. Clin Cancer Res (2006) 0.96
Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer. J Nucl Med (2011) 0.96
Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model. Clin Cancer Res (2012) 0.96